Compare Global Payments Inc (GPN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs TG Therapeutics Inc — how do they compare? Global Payments Inc trades at $82.2 (market cap $21.46B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Global Payments Inc is far larger — about 2.6× TG Therapeutics Inc's market cap, and Global Payments Inc pays a 1.23% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and TG Therapeutics Inc for 16 Days on average.
| GPN | TGTX | |
|---|---|---|
Market Cap | $21.46B | $8.16B |
Volume | 1,482,600 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $94.83 | $59.06 |
52-Week Low | $62.47 | $26.94 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | $39.60B | $8.37B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.77, up 2.08% with a neutral technical signal despite bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net income margin and ROE. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains strongly bullish with a $102.75 price target.
GPN presents a mixed outlook with strong analyst support and strategic initiatives offset by profitability concerns and rising debt levels. The stock offers 24% upside to consensus targets but faces execution risks in integrating acquisitions and maintaining margin expansion amid competitive pressures in the payments technology sector.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
